In this regard, our results indicating KDM3A as a key epigenetic factor controlling ovarian CSCs may offer a new perspective to develop an inhibitor that specifically target KDM3A to eliminate CSC population and overcome chemoresistance in ovarian cancer. This evidence concerns the gene KDM3A and ovarian cancer.